- Good Clinical Practice (can be GFDA or from different organization as long as not expired)
- Reference lab
- Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for Strongyloides), with a lab in Accra still to be identified.
- Frame messaging on why doing clinical trial as based on Trichuris burden – evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible
- GHS to review external communications plan – Tuesday 19th
- Consider how to reflect non-STH diseases also addressed by the FDC (e.g. Onchocercosis, Limphatic Filariasis, Scabies). This was consulted with the Comms team an we are not sure it is a good idea. Perhaps we can think about doing posters and material to be left to the sites after the project, but not during the study, to avoid confussion.
- Materials for Ghana (posters on STH) will be developed in collaboration with GHS to be used in awareness campaigns before the study.
- Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement reported coverage data.
- Economics – Contributes also to WP3 (KEMRI)
- GHS RDD to consider options for inclusion of key costing data points
